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We studied the effect of acrolein, an a,b-unsaturated aldehyde that causes adduct-modiﬁcation of
lysine, cysteine, and histidine residues, on antithrombin, a key anticoagulant serpin. Intrinsic ﬂuo-
rescence, functionality (anti-FXa and anti-IIa activity), heparin afﬁnity and conformational features
of plasma and puriﬁed antithrombin were evaluated. In vivo experiments were carried out in mice.
Intrinsic ﬂuorescence showed a two-step conformational change. Acrolein, even at low dose,
impaired the anticoagulant function of puriﬁed antithrombin by affecting its heparin afﬁnity. How-
ever, higher concentrations of acrolein and long incubations are required to cause mild functional
effects on plasma antithrombin and mice.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Thrombosis is a multifactorial disorder, with both congenital
and acquired risk factors. So far, most of the research on venous
thrombosis has been focused on the identiﬁcation of genetic risk
factors; however, few environmental risk factors have been de-
scribed in the last 10 years [1–3]. Diet, healthy life conditions
and consumer habits usually tip the scale in the disease or the
health favours, but few studies have investigated the elements in-
volved and their consequences on the functionality of factors of the
hemostatic system.
Acrolein is a highly electrophilic a,b-unsaturated aldehyde to
which humans are exposed in industrial, environmental, and
therapeutic situations. Its use as an herbicide, as starting material
for acrylate polymers, as well as in the production of acrylic acid
makes it potentially dangerous. Moreover, acrolein is found in
cigarette smoke, in the exhaust from internal combustion engines,
and in the vapours of overheated cooking oil [4]. In vivo, acrolein is
a metabolic product of the anticancer drug cyclophosphamide and
has been found to be formed from the metabolism of the threonine
by neutrophil myeloperoxidase at sites of inﬂammation [4]. Inter-chemical Societies. Published by Eestingly, it causes oxidative modiﬁcation of proteins by reacting
with the sulfhydryl side chain of cysteines, e-amino groups of ly-
sines, and the imidazole group of histidines, being lysines the pre-
ferred residues [4]. Acrolein protein adducts have been
demonstrated in diabetic nephropathy [4], and Alzheimer’s disease
[4], both of which are associated with increased lipid peroxidation.
Actually, lipid peroxidation is related to increased risk of thrombo-
sis due to the activation of the coagulation system and the forma-
tion of thrombin by activated platelets [4]. A recent study found a
signiﬁcant functional effect of acrolein on antithrombin, the main
endogenous anticoagulant [2]. The aim of this study was to charac-
terize in vitro and in vivo the effect of acrolein on the functionality
and conformation of antithrombin and its implication in the risk of
thrombosis that has been described in situations with increased
levels of this aldehyde.2. Materials and methods
2.1. Reagents
Puriﬁed human antithrombin was obtained from commercial
concentrates (Kybernin-P, ZLB Behring, Germany). Acrolein was
purchased from Sigma (Spain). Low molecular weight heparinlsevier B.V. All rights reserved.
Fig. 1. Dose- and time-dependent effect of acrolein on anticoagulant activity of
antithrombin. (A) Anti-FXa activity in presence of LMWH and (B) anti-FIIa activity
in presence of UFH. Experiments were run in triplicate and data are presented as
mean ± S.E.
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from Laboratorios Rovi S.A. (Spain). LMWH has a size of 3600 Da
while unfractionated heparin (UFH) has an average size of
20 000 Da.
2.2. Plasma samples
Venous blood obtained from humans (who gave their informed
consent to enter the study, which was approved by the local ethic
committee and performed according to the declaration of Helsinki
in 2000), and mice was anticoagulated with 10 mM trisodium cit-
rate. Fresh plasma was obtained by centrifugation and stored at
70 C.
2.3. In vitro incubation of antithrombin with acrolein
Acrolein was diluted in 10 mM sodium phosphate buffer, pH 7.4
containing 150 mM NaCl. Puriﬁed antithrombin or plasma samples
were incubated in absence or presence of 0–2 mM acrolein at
37 C for 0–24 h. In heparin protection studies, 0.1 U/ll of LMWH
was used.
2.4. In vivo effects of acrolein on antithrombin
Non-inbred Swiss (ICR CD-1TM) male mice between 8 and
10 weeks old weighing 30–35 g were used for acrolein injection.
Ten milligrams of acrolein per kilogram of mouse body weight
or vehicle (saline) were injected into the tail vein of the animal.
Mice were anesthetized with isoﬂuorane and blood samples were
drawn in citrate through the retro-orbital plexus using heparin-
coated micro-hematocrit capillaries before and 24 h after acrolein
injection. Plasma samples were stored at 70 C. All experimental
procedures were performed in accordance with the approved
Institutional Animal Care Guidelines from the University of
Murcia.
2.5. Measurement of antithrombin activity
Antithrombin activity was determined by chromogenic meth-
ods, as previously described [5]. Anti-factor Xa (anti-FXa) assay
was performed with LMWH, bovine FXa, and S-2765 chromo-
genic substrate (Chromogenix, IZASA, Spain), while anti-factor
IIa (anti-FIIa) activity was measured with human thrombin,
and S-2238 chromogenic substrate in the presence and absence
of UFH (Chromogenix, IZASA, Spain). Values were expressed as
a percentage of the result observed in a control pool of citrated
plasma from 100 healthy subjects or a pool of plasma from 10
control mice (100%).
2.6. Electrophoretic analysis of antithrombin
Crossed immunoelectrophoresis of antithrombin in presence of
heparin was carried out as previously described [6]. Separation of
proteins was evaluated by SDS–PAGE, non-denaturing PAGE and
immunoblotting as indicated elsewhere [7].
2.7. Fluorescence measurements
The effect of acrolein on tertiary structure of antithrombin was
analyzed by ﬂuorescence emission spectra on a Cary Eclipse spec-
troﬂuorometer. Intrinsic tryptophan emission spectra of puriﬁed
antithrombin were monitored by an excitation at 295 nm and
emission at 305–405 nm. The slit-widths were set at 5 nm for
both excitation and emission and a constant scan rate of
400 nm/min was used. The ﬁnal antithrombin concentration
was 600 nM.2.8. Statistical analysis
Statistical analysis was performed by Statistical Package for So-
cial Science (version 15.0; SPSS, USA). Data were presented as
mean ± standard error (S.E.). Differences of plasma anti-FXa activ-
ity were analysed by unpaired two tailed Student’s t-test. Statisti-
cal signiﬁcance was taken as P < 0.05.
3. Results
3.1. Effects of acrolein on puriﬁed antithrombin
Fig. 1 shows the time- and dose-dependent effects of the in vitro
incubation of acrolein on the anticoagulant function of puriﬁed
antithrombin. Anti-FXa and anti-FIIa activities were statistically re-
duced after incubation with acrolein at all tested concentrations
and times of incubation, leading to an almost complete inhibition
of the antithrombin activity at 0.5 h of incubation with 2 mM of
acrolein.
Although no signiﬁcant changes were observed by SDS gels
(Fig. 2A), we detected signiﬁcant electrophoretic changes on anti-
thrombin by non-denaturing gels, both in the absence and pres-
ence of urea (Fig. 2B and C). Both, native and latent forms of
antithrombin increased the electrophoretic mobility in a process
that was time- and dose-dependent of acrolein and correlated with
the loss of activity. However, we did not observe polymers neither
in SDS nor in native gels (Fig. 2A and B).
Fig. 2. Electrophoretic changes induced by acrolein on puriﬁed antithrombin. (A) SDS–PAGE, (B) non-denaturing PAGE and (C) non-denaturing PAGE + 6 M urea.
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dues involved in the heparin binding, samples incubated with 0, 1
and 2 mM acrolein for 30 min were run in crossed immunoelectro-
phoresis gels (Fig. 3). Acrolein treatment completely transformed
the protein to a form with low heparin afﬁnity (Fig. 3). This was
not the result of a transition of the native to the latent conforma-
tion, as the latent form did not increase after acrolein incubation.
Thus, acrolein must affect the heparin-binding site of antithrom-
bin. Therefore, we incubated puriﬁed antithrombin with LMWH
or saline for 30 min at 22 C before treatment with 0–2 mM acro-
lein. The binding of heparin to antithrombin signiﬁcantly reducedthe acrolein-dependent loss of anticoagulant activity (Fig. 4A).
Moreover, although heparin delayed the electrophoretic shift
caused by acrolein, antithrombin–heparin complex still had faster
electrophoretic mobility on native gels (Fig. 4B), suggesting the
affectation of other residues located out of the heparin-binding
site. However, the residues affected besides those located at the
heparin-binding site should not be decisive in the inhibitory func-
tion since antithrombin treated with 2 mM acrolein showed al-
most no impairment of its progressive anti-FIIa activity, in the
absence of heparin (80.8 ± 2.5% and 76.3 ± 2.9% at 0.5 and 1.5 h
of incubation with acrolein, respectively).
Fig. 3. Crossed immunoelectrophoresis of antithrombin in the presence of heparin.
Puriﬁed antithrombin was incubated for 30 min with 0, 0.5 and 1.5 mM acrolein.
The antithrombin forms of high and low heparin afﬁnity are indicated with arrows.
Fig. 5. Fluorescence intensity changes at 332 nm of antithrombin incubated with
0–2 mM of acrolein for 24 h. The solid line (—d—) represents control antithrombin
and the dashed lines represent antithrombin treated with different acrolein
concentrations: 0.5 mM (  s  ), 1 mM (- - -.- - -), 1.5 mM (--5--) and 2 mM
(–j–).
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Steady-state tryptophan emission spectra of antithrombin were
recorded for each of the concentration of acrolein and times ofFig. 4. Protective effect of heparin on puriﬁed antithrombin treated with acrolein. (A) Ef
100% activity was set with the untreated protein. The chromogenic assay was perform
Experiments were run in duplicate and data are presented as mean ± S.E. (B) Electrophoincubation (data not shown). The concentration-dependent acro-
lein impact on antithrombin was highlighted by subtracting the
differences of emission spectra of the wild-type molecule to that
with the respective acrolein dose. The intrinsic ﬂuorescence of
the protein treated with acrolein showed no changes in the emis-
sion maxima wavelength (kmax: 332 nm). However, we observed
signiﬁcant changes in the ﬂuorescence intensity at 332 nm when
antithrombin was incubated with various acrolein concentrations,
suggestive of a two-steps conformational transition in antithrom-
bin (Fig. 5). During short incubation periods (0.5 h), an unfolding
transition was observed by an increase in tryptophan ﬂuorescence
(from 14% for 0.5 mM acrolein to 25% for 2 mM acrolein) (Fig. 5),
probably due to a higher solvent-exposition of tryptophans. Con-fects on the anti-FXa (left) and anti-FIIa (right) activity after acrolein treatment. The
ed without adding heparin in those reactions that were incubated with heparin.
retic changes induced by acrolein in the presence and absence of heparin.
Fig. 6. Electrophoretic changes of plasma antithrombin by effect of acrolein. (A)
Non-denaturing PAGE. (B) Crossed immunoelectrophoresis of samples incubated
24 h with or without acrolein. The antithrombin forms of high and low heparin
afﬁnity are indicated with arrows. (C) Protective effect of heparin on antithrombin
under incubation with acrolein by non-denaturing PAGE. AT: antithrombin; LMWH:
low molecular weight heparin.
Fig. 7. Structural representation of the accessibility and position of the lysine
residues in antithrombin. Dark blue colour is attributed to completely buried
residues, whereas red colour is attributed to residues with at least 75% of their
relative surface accessible. Helices involved in heparin binding are coloured in
violet.
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marked decrease in ﬂuorescence signal (Fig. 5), even minor than
wild-type antithrombin (from 14% for 0.5 mM acrolein to 37%
for 2 mM acrolein).
3.3. Effects of acrolein on plasma antithrombin
Antithrombin activity was only mildly affected at the highest
concentration of acrolein and after 24 h of incubation (anti-FXaof plasma treated with acrolein 81.7 ± 6.6% vs. control plasma
103.6 ± 4.7%; P < 0.01). Consistent with this result, electrophoretic
analysis of plasma antithrombin also found a slight electrophoretic
shift, similar to that identiﬁed when using puriﬁed antithrombin
(Fig. 6A). Moreover, crossed immunoelectrophoresis revealed a
slight increase of the form with low heparin afﬁnity (Fig. 6B). Final-
ly, as for puriﬁed antithrombin, LMWH seemed to protect against
the minor electrophoretic changes induced by acrolein on plasma
antithrombin (Fig. 6C).
3.4. In vivo effects of acrolein on antithrombin
The decrease of antithrombin activity in plasma samples incu-
bated with acrolein prompted us to study the in vivo effect of this
compound on antithrombin in the context of a living animal. Anti-
thrombin activity was slightly but statistically lower in mice in-
jected with acrolein than in control mice (81.9 ± 2.9% vs.
90.6 ± 1.2%, respectively; P = 0.039). Thus, concentrations of acro-
lein in the range of 1–3 mM reduced the activity of antithrombin
within 24 h from injection into a mouse.
4. Discussion
Antithrombin is a structurally modulate protein whose ﬂexibil-
ity deﬁnes its adequate functionality to control the coagulation [8].
Any modiﬁcation that concludes in a change of its ﬂexibility or af-
fects its functional domains provokes a decrease in its activity [9].
Genetic modiﬁcations affecting the coding sequence of this serpin
may have any of these consequences leading to a state of deﬁ-
ciency that signiﬁcantly increases the risk of thrombosis [10].
Within the environmental agents that are able to modify the func-
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of acrolein have been described in situations with thrombotic risk,
such as smoking [4,11,12], treatment with cyclophosphamide or
renal failure [4]. Moreover, phagocytes generate acrolein by action
of myeloperoxidase on threonine residues in atheroma plaques
leading to a microenvironment with high local concentrations of
this aldehyde [13–15]. Additionally, a recent report described the
functional effects of acrolein on antithrombin in vitro [2]. We con-
ﬁrmed that acrolein causes the loss of activity of antithrombin,
particularly its anti-IIa activity, although no polymerization was
detected, as the suggested mechanism involved in the loss of its
activity [2]. Indeed, the electrophoretic data support that the loss
of activity caused by acrolein on antithrombin was mainly due to
the modiﬁcations caused by this agent on the serpin. Acrolein ad-
ducts reduce the positive charges in the protein since mainly lysine
residues are modiﬁed. These modiﬁcations primarily affect the
heparin-binding domain, where some lysine residues are exposed
(Fig. 7). Modiﬁcation of these residues, particularly Lys11, Lys114
and Lys125 impairs the binding of heparin, which triggers the acti-
vation of the molecule [16,17]. Indeed, most circulating antithrom-
bin has a native state with low anticoagulant properties, because
the reactive centre loop (RCL) is partially inserted into the top of
the A b-sheet of the protein. The binding of glycosaminoglycans
to the heparin-binding site expels the RCL leading to the active
state [18,19]. According to these results, we showed that heparin
protects antithrombin against the functional and electrophoretic
effects caused by acrolein, but it is not able to completely abolish
them, which seems to suggest that acrolein must modify other res-
idues beside those located at the heparin-binding domain. These
additional residues must not be crucial for antithrombin function,
as the progressive activity is not severely disturbed, but could ex-
plain why the effect induced by acrolein on antithrombin inactiva-
tion of FIIa and FXa is slightly different. Indeed, residues other than
R393 are involved in the different reactivity of antithrombin with
its target proteases [20,21].
Fluorescence measurements by intrinsic tryptophan emission
showed that acrolein induces two main changes in antithrom-
bin. A ﬁrst change characterized by a non-stable conformation
transition associated to an increase of 14–25% of tryptophan
ﬂuorescence correlated with the loss of heparin afﬁnity. Longer
incubations must result in modiﬁcation of additional residues
that caused a second conformational change with a signiﬁcantly
decrease around of 37% ﬂuorescence intensity, which would be
associated with a reorganization of tryptophans in the core of
molecule. Thus, our results suggest that the ﬂuorescence of
any of four tryptophans of antithrombin (Trp-49, -189, -225
or -307) [22] could be affected by the acrolein treatment, prob-
ably by modifying Lys, Cys or His residues located close to
tryptophan residues. This analysis also revealed a dose-depen-
dently effect (Fig. 5). This result, together with the electropho-
retic analysis, suggests that low concentrations of acrolein (0.5
and 1 mM) might only form adducts with certain accessible
residues, while higher concentrations would also affect buried
residues.
We have also determined whether the observed in vitro effects
of acrolein on antithrombin may have clinical consequences by
using plasma samples and in vivo experiments performed in
mice. Our results suggest that only high concentrations of acro-
lein (2 mM), probably barely achieved under a small amount of
conditions, are required to cause minor effects (but the same
identiﬁed in vitro) on antithrombin. Therefore, we think that
although increased levels of acrolein may contribute to the risk
of thrombosis, particularly if combined with other additive or
synergistic factors, its clinical relevance in thrombosis might be
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